Terminalia Arjuna (Oxyjun®)

Terminalia arjuna
Evidence Level
Limited
2 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Terminalia arjuna is a large deciduous tree native to India whose bark has been used in Ayurvedic cardiology for over 3,000 years — described in the Ashtanga Hridayam as the premier cardiac tonic. In small trials, generic arjuna bark extract reduced angina frequency and improved treadmill exercise tolerance in men with stable angina, and a separate small study reported higher aerobic capacity and lower resting systolic blood pressure in healthy young adults. Oxyjun® (E-OJ-01) is a standardized arjuna bark extract developed by Enovate Biolife (now part of OmniActive Health Technologies); its exercise-performance trial is manufacturer-run and not indexed in PubMed, and its one published trial measured heart-imaging markers rather than exercise outcomes.

Studied Dose 400 mg/day Oxyjun® in the single published, manufacturer-run heart-function trial; generic arjuna was used at 500 mg three times daily in the angina trial.
Active Compound Arjunolic acid, arjunic acid, arjunetin, terminoic acid, and tannins — Oxyjun® (E-OJ-01), a standardized Terminalia arjuna bark extract developed by Enovate Biolife (now part of OmniActive Health Technologies)

Benefits

Cardiorespiratory endurance improvement

A manufacturer-run trial of Oxyjun® (500 mg/day for 4 weeks) reported higher VO2 max versus placebo in healthy adults. This trial is not indexed in PubMed and has not been independently replicated, so the size of the effect cannot be confirmed. In a separate small study, generic arjuna bark extract (500 mg/day) also raised VO2 max in a group of about 10 healthy young adults.

Circulatory and heart-function support

In one small crossover trial in 58 men with stable angina, generic arjuna bark extract (500 mg three times daily, each arm lasting about one week) reduced angina frequency and improved treadmill exercise tolerance to a degree similar to isosorbide mononitrate, and was well tolerated. That study enrolled men only, did not measure ejection fraction, and used generic arjuna rather than Oxyjun. A separate manufacturer-run trial of Oxyjun (400 mg/day for 8 weeks) reported a small rise in left-ventricular ejection fraction in healthy adults.

Blood pressure and arterial health

In a small study of healthy young adults, generic arjuna lowered resting systolic blood pressure. Controlled trials in people with high blood pressure are lacking, so a specific millimetre-of-mercury effect cannot be stated.

Exercise-induced oxidative stress reduction

Arjuna bark is rich in tannins and flavonoids that scavenge free radicals in laboratory tests. Whether oral arjuna lowers exercise-induced oxidative stress, muscle damage, or recovery time in people has not been shown in the trials cited here.

Lipid profile improvement

Some early studies suggest arjuna may modestly affect blood lipids, but the trials cited here did not establish a clear cholesterol-lowering effect in people. The proposed mechanisms come from laboratory work.

Mechanism of action

1

Endothelial nitric oxide enhancement

Arjunolic acid and arjunic acid stimulate endothelial nitric oxide synthase (eNOS) activity and increase bioavailable nitric oxide — improving vascular tone, reducing blood pressure, and enhancing blood flow to working muscle tissue during exercise. This mechanism underlies both cardiovascular protection and performance enhancement.

2

Cardiac muscle calcium channel modulation

Arjuna glycosides modulate cardiac L-type calcium channels, improving cardiac contractility and stroke volume without the proarrhythmic risks associated with pharmaceutical calcium channel modulators. This proposed effect comes from laboratory work and has not been confirmed as the cause of any clinical benefit in people.

3

Free radical scavenging and antioxidant enzyme induction

Arjuna's dense tannin matrix (including arjunagenin and terminic acid) directly scavenges reactive oxygen species and induces endogenous antioxidant enzyme expression (SOD, catalase, GPx), providing both immediate and sustained antioxidant protection in cardiac and vascular tissue.

Clinical trials

1
Oxyjun® and VO2 Max in Healthy Adults — RCT

Randomized, double-blind, placebo-controlled trial of Oxyjun® (500 mg/day) vs. placebo in 30 healthy adults for 4 weeks. (Manufacturer-sponsored; not indexed in PubMed.)

30 healthy adults. 4-week intervention.

Oxyjun® supplementation was reported to increase VO2 max versus placebo. Significant improvements in cardiorespiratory fitness markers and exercise performance indices. Well-tolerated with no adverse effects. This trial is manufacturer-sponsored and is not independently published or PubMed-indexed, so the effect size should be viewed with caution.

2
Terminalia arjuna vs. Isosorbide Mononitrate in Stable Angina — RCT
PubMed

Randomized double-blind crossover trial comparing generic arjuna bark extract (500 mg three times daily) vs. isosorbide mononitrate (40 mg/day) vs. placebo in 58 men with stable angina, each treatment given for about one week separated by a washout.

58 men with stable angina. Each treatment arm lasted about one week in a crossover design. Generic arjuna extract, not Oxyjun.

Arjuna extract significantly reduced angina frequency and improved treadmill exercise tolerance compared with placebo, to a degree similar to isosorbide mononitrate, and was well tolerated. Ejection fraction was not measured. Because this trial used generic arjuna in men only, it does not establish the branded Oxyjun product's effects.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated at supplemental doses
High-dose whole bark preparations may cause mild GI discomfort
Potential for excessive blood pressure lowering in already-hypotensive individuals

Important Drug interactions

Antihypertensive medications — additive blood pressure-lowering effects; monitor blood pressure
Cardiac medications (digoxin, beta-blockers, calcium channel blockers) — arjuna has direct cardiac effects; potential additive or synergistic effects; monitor cardiac parameters
Anticoagulants — tannin content may mildly affect coagulation; monitor with warfarin
Antidiabetic medications — mild glucose-lowering activity; monitor blood sugar

Frequently asked questions about Terminalia Arjuna (Oxyjun®)

What is Terminalia Arjuna?

Terminalia arjuna is a large deciduous tree native to India whose bark has been used in Ayurvedic cardiology for over 3,000 years — described in the Ashtanga Hridayam as the premier cardiac tonic.

What is Terminalia Arjuna used for?

Terminalia Arjuna is researched primarily for Cardiovascular and Athletic Performance. A manufacturer-run trial of Oxyjun® (500 mg/day for 4 weeks) reported higher VO2 max versus placebo in healthy adults. This trial is not indexed in PubMed and has not been independently replicated, so the size of the effect cannot be confir…

What is the recommended dosage of Terminalia Arjuna?

The clinically studied dose is 400 mg/day Oxyjun® in the single published, manufacturer-run heart-function trial; generic arjuna was used at 500 mg three times daily in the angina trial. Always follow the product label and check with a healthcare provider for personal advice.

Is Terminalia Arjuna safe, and does it have side effects?

For most healthy adults, Terminalia Arjuna is well tolerated at studied doses. Reported effects can include: Generally well tolerated at supplemental doses High-dose whole bark preparations may cause mild GI discomfort It may also interact with some medications. Terminalia Arjuna is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Terminalia Arjuna interact with any medications?

Possible interactions include: Antihypertensive medications — additive blood pressure-lowering effects; monitor blood pressure Cardiac medications (digoxin, beta-blockers, calcium channel blockers) — arjuna has direct cardiac effects; potential additive or synergistic effects; monitor cardiac parameters If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Terminalia Arjuna?

NutraSmarts rates the evidence for Terminalia Arjuna as Limited (2 out of 5). It is backed by 2 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Maulik SK, Katiyar CK. Terminalia arjuna in cardiovascular diseases: making the transition from traditional to modern medicine in India. Curr Pharm Biotechnol. 2010;11(8):855-60..PubMedUsed to support: Narrative review of Terminalia arjuna in cardiovascular disease. It notes the cardioprotective effects are demonstrated mainly in animal models, with some small human studies in chronic stable angina, endothelial dysfunction and heart failure, and states that drug standardization, toxicity data and large multicentre randomized trials are still lacking before mainstream use is justified.
  2. Srivastava S, Girandola RN, Abedon B. Effect of E-OJ-01 on Left Ventricular Ejection Fraction and Myocardial Oxygen Consumption: A Randomized, Double-Blind, Placebo-Controlled Study. J Multidiscip Healthc. 2022;15:2511-2525..PubMedUsed to support: Manufacturer-funded trial (Enovate Biolife/Innophos) of Oxyjun (E-OJ-01) at 400 mg/day for 8 weeks in 72 healthy adults aged 30-70. Left-ventricular ejection fraction rose 6.28% from baseline versus 0.24% with placebo, alongside a lower fatigue score. This is a heart-imaging surrogate rather than a clinical outcome, and there is no independent replication.
  3. Bharani A, Ganguli A, Mathur LK, Jamra Y, Raman PG. Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate. Indian Heart J. 2002;54(2):170-5..PubMedUsed to support: Double-blind placebo-controlled crossover trial in 58 men with chronic stable angina. Generic arjuna bark extract (500 mg three times daily, about one week per arm) reduced angina frequency and improved treadmill exercise tolerance, similar to isosorbide mononitrate, and was well tolerated. Men only; ejection fraction was not measured; this is generic arjuna, not the Oxyjun product.
  4. Sandhu JS, Shah B, Shenoy S, Chauhan S, Lavekar GS, Padhi MM. Effects of Withania somnifera (Ashwagandha) and Terminalia arjuna (Arjuna) on physical performance and cardiorespiratory endurance in healthy young adults. Int J Ayurveda Res. 2010;1(3):144-9..PubMedUsed to support: Small trial in 40 healthy young adults. The arjuna-only arm (about 10 subjects, 500 mg/day generic bark extract for 8 weeks) raised VO2 max and lowered resting systolic blood pressure. Generic arjuna, not Oxyjun; very small sample; no clinical disease endpoints.